Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019–2021: a repeat cross-sectional study
Abstract Background: One of the objectives of cannabis legalization in Canada is to transition consumers from the illegal to the…
Tom P. Freeman
Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder
Abstract Rationale: Chronic cannabis use is associated with impaired cognitive function. Evidence indicates cannabidiol (CBD) might be beneficial for treating…
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
Abstract As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful…
Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act
Abstract Background and aims: The United Kingdom (UK) Psychoactive Substances Act (PSA), implemented on the 26th May 2016, made the…
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study
Abstract Rationale: There is growing interest in the therapeutic potential of cannabidiol (CBD) across a range of psychiatric disorders. CBD…
Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
Abstract Cannabis use peaks during adolescence and emerging adulthood, and cannabis use disorder (CUD) is associated with a wide range…
The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use
Abstract Background: The lack of an agreed international minimum approach to measuring cannabis use hinders the integration of multidisciplinary evidence…
Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis
Abstract Synthetic cannabinoid receptor agonists (SCRAs) may be used as an alternative to natural cannabis; however, they may carry a…
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study
Abstract Background: Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder.…
Supporting Future Cannabis Policy – Developing a Standard Joint Unit: A Brief Back-Casting Exercise
Abstract The standardization of cannabis doses is a priority for research, policy-making, clinical and harm-reduction interventions and consumer security. Scientists…